Phase 3 Myeloma Trial, Recruiting NCT07297329 Sponsor: Sinocelltech Ltd. Condition: Myeloma
Back to Myeloma

Phase 3 Myeloma Trial, Recruiting

NCT07297329
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been recently diagnosed with multiple myeloma (a type of blood cancer) according to standard diagnostic guidelines, and a bone marrow transplant is not a suitable option for you.
  • Your multiple myeloma can be measured and tracked through tests (meaning there are clear signs of the disease that can be monitored).
  • Your heart, liver, kidneys, and blood counts are working well enough to meet the study's requirements.
  • You are willing to use contraception during the study and for 5 months after the last dose, and you agree not to donate eggs or sperm during this time.

Who may not be able to join:

  • You have another type of blood cancer in addition to multiple myeloma.
  • There is evidence or suspicion that the cancer has spread to your brain or the fluid around your brain or spinal cord.
  • You have an infection that is not currently under control.
  • You have a serious ongoing health condition affecting your heart, lungs, hormones, immune system, liver, or digestive system, or you have another type of cancer — and your doctor considers this to be a significant concern (confirm with trial site).
  • You have had major surgery or a serious injury within the 4 weeks before starting the trial, or you are expected to need planned surgery during the trial.
  • You have received a live or weakened vaccine within 30 days before your first dose, or you are currently breastfeeding.
  • You have a mental health condition, difficulty following medical instructions, or any other reason the trial doctors feel makes participation unsuitable for you (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Sinocelltech Ltd.
Registry
ClinicalTrials.gov
Start date
29 December 2025
Est. completion
1 December 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Progression free survival (PFS); Minimal residual disease (MRD) negativity rate for participants with CR

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov